T1D Fund
By The Numbers
$250M +
in assets under management
20+
active portfolio companies
%100
of T1D Fund returns reinvested to propel progress
~9M
people living with T1D globally
$30B
annual cost of T1D treatment
Who We Are
We are a dedicated team of venture, pharma, biotech, company building, and business development veterans dedicated to catalyzing a world without T1D. Managing an active portfolio of 25+ companies with over $250 million in assets under management, we act as subject matter experts who strategically invest to accelerate T1D treatments and cures.
Led by a deeply experienced team of healthcare and investment professionals, working in partnership with an independent Investment Committee, the Fund leverages its and Breakthrough T1D’s vast research, clinical, regulatory, and medical affairs network on behalf of its portfolio companies.
Learn more about the T1D Fund’s governance and structureHow We Invest
The T1D Fund operates as a powerful platform for collaboration, using catalytic capital and expertise to de-risk investments and create a flywheel effect that attracts other investors to the T1D space. We partner with innovators to accelerate the development of disease-modifying therapies and cures. All returns are reinvested, creating a continuous cycle of progress that fuels foundational research and accelerates program development.
Discover Our Approach